Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://www.ncbi.nlm.nih.gov/pubmed/33282288
http://dx.doi.org/10.3892/mco.2020.2175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://www.ncbi.nlm.nih.gov/pubmed/33282288
http://dx.doi.org/10.3892/mco.2020.2175

Ejemplares similares